Navigation Links
PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Date:8/20/2007

Novel cardioprotective agent to move forward in Phase III development

NEW YORK, Aug. 20 /PRNewswire/ -- PeriCor Therapeutics announced today that its licensing agreement for acadesine with Schering-Plough Corporation has become effective. The agreement grants Schering-Plough exclusive worldwide rights for the development and commercialization of PeriCor's lead compound, acadesine. Financial terms of the transaction were not disclosed.

Acadesine is currently under evaluation in Phase III clinical development as an intravenous infusion for the prevention of adverse cardiovascular and cerebrovascular outcomes that occur as complications associated with ischemia-reperfusion injury in patients undergoing coronary artery bypass graft (CABG) surgery. Acadesine has been studied in placebo-controlled trials that enrolled more than 4,000 patients. Schering-Plough will conduct an additional randomized, placebo-controlled Phase III trial needed for regulatory approval. An agent, such as acadesine, that can be shown to reduce the surgical complications of stroke, heart failure and death that can accompany CABG would not only make an important contribution to patients' well-being, but would also be anticipated to reduce health care costs dramatically.

"Schering-Plough possesses the vital organizational and financial resources to complete the clinical and regulatory processes required to make this life-saving medicine available to cardiac surgeons and anesthesiologists around the world," said Richard R. Stover, President and Chief Executive Officer of PeriCor Therapeutics. Commenting further, Mr. Stover said, "We are especially impressed with the caliber of Schering-Plough's cardiovascular group in clinical development, medical, and marketing activities and their unparalleled record of innovation in this therapeutic area."

Previous clinical experience with acadesine in placebo-controlled studies in CABG surgery suggests that acadesine may have unique
'/>"/>

SOURCE PeriCor Therapeutics, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. Speaker announces business members of IT Task Force
3. Doyle announces technology tax credits for Berbee
4. Doyle announces new energy, global warming policies
5. Doyle announces $80M renewable energy strategy
6. GE announces first installation of Discovery VCT
7. UWM announces winners of RGI awards
8. Third Wave announces two senior management appointments
9. Mirus announces new method for making antibodies
10. Merge announces sofware updates, upcoming acquisition
11. Small Tree announces ethernet solution for Apple Xserv G5

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)..., BETHESDA, Md., Nov. 19 /PRNewswire-FirstCall/ ...ator in biotechnology for diabetes therapy, and a ...rvices to food, supplement, biotechnology and phar...e previously reported $6.3 million registered dire...70 shares of its common stock and warrants to purc...
(Date:11/19/2009)..., Nov. 19 /PRNewswire/ - Aegera Therapeutics Inc. ... a randomized Phase 2B study of AEG35156, a target...for multiple oncology indications. ,, The study... of the X-Linked Inhibitor of Apoptosis (XIAP) Ant...e Cytarabine and Idarubicin in AML Following Failu...
(Date:11/18/2009)...lif., Nov. 18 Marrone Bio Innovati...and commercialization of effective and environment...ed that it has been named an IC20 company by the I...rgest national angel investing group. ,, Compan... to rewarding results for all stakeholders, includ...
(Date:11/18/2009)...D, Calif., Nov. 18 Sanga...day that data from the University of Pennsylvania ...gamo,s zinc finger nuclease (ZFN) based product, S...turely disclosed on the internet. ,, Data were ... Pennsylvania School of Medicine from a single sub...
Breaking Biology Technology:Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
..., Jan. 13 Cumberland Pharmaceuticals Inc.,is plea...oduct Director. In,this role, Mr. Lee will draw up...ing experience to lead the prospective launch and ... , (Photo: http://www.newscom.com/cgi-bin/pr...ased to welcome Mr. Lee to Cumberland,s management...
...3 /PRNewswire-Asia-FirstCall/ -- American Oriental...he Company"), a leading marketer,distributor and m...cts in,China, today announced that the PRC governm... of China, the Ministry of Finance and the State A...f the company,s subsidiaries, Heilongjiang,Songhua...
... NEW HOPE, Pa., Jan. 13 Jubilant Organosys,Ltd., ...today that its,Bangalore-based subsidiary, Jubilan...artnership with BioLeap, LLC, USA. Under this par...eap,s leading edge computational fragment,based dr...emistry, biology and,crystallography to offer a hi...
Other Biology Technology:PRC Government Grants High-Tech Status to AOBO Subsidiaries 2PRC Government Grants High-Tech Status to AOBO Subsidiaries 3Jubilant and BioLeap Announce New Partnership in Drug Discovery 2Jubilant and BioLeap Announce New Partnership in Drug Discovery 3
(Date:11/20/2009)...searchers are at work on many scientific and techn...n has recently provided support that totals nearly...wing investigators under the American Recovery and...have been awarded grants for investigation of sola...sor of physics, will enhance the capabilities of N...
(Date:11/20/2009)...hly precise measurements of plasma lipoprotein con...ce spectroscopy (NMR), researchers led by Daniel C... Medical School in Boston, MA, the Framingham Hear...m in Stockholm, Sweden and Oxford, England perform...enome among 17,296 women of European ancestry from...
(Date:11/20/2009)...gton, DC Nov. 20, 2009) Scientists from the Mari...ions of the Naval Research Laboratory (NRL) organi...ientists on an Arctic expedition to initiate metha...ermine the spatial variation of sediment contribut...S. Coast Guard Cutter Polar Sea as a research plat...
Breaking Biology News(10 mins):NJIT receives NSF funding to improve Big Bear Telescope, study solar energy 2Genetic analysis helps dissect molecular basis of cardiovascular disease 2International expedition investigates climate change, alternative fuels in Arctic 2U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 1U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 2U M Doctor Working to Get Neurologists in the Game When it Comes to Sports Injuries 59318 3Blue Cross Names Three New Executives 59315 1Blue Cross Names Three New Executives 59315 2Blue Cross Names Three New Executives 59315 3Varian Inc Delivers a Productivity Increase of Up to 100 25 With Its 710 ES Series ICP OES 5406 1Varian Inc Delivers a Productivity Increase of Up to 100 25 With Its 710 ES Series ICP OES 5406 2Varian Inc Delivers a Productivity Increase of Up to 100 25 With Its 710 ES Series ICP OES 5406 3
...nc., a clinical-stage biopharmaceutical company fo...s of epidemic potential, announced today that the ...ropean Medicines Agency (EMEA) independently revie...gencies granted SQ109 orphan drug status for the t... vitro and in vivo activity against drug-susceptib...
...rnational collaboration, more than 200 medical and...his week on the relationship between poverty and h...he Council of Science Editors, includes presentati... webcast live from the National Institutes of Heal...nih.gov/summary.asp?live=6239 , Two of the selec...
...hnology has joined forces with the world,s largest...logies that will provide an economical, green fuel...Bligh today announced the multi-million dollar dea...Bioindustries, supported by the Queensland Governm...nta Centre for Sugarcane Biofuel Development" at Q...
Other Biology News:Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 2Sequella receives US and EU orphan drug status for SQ109 for the treatment of TB 3200 journals join in theme issues on poverty and human development 2200 journals join in theme issues on poverty and human development 3200 journals join in theme issues on poverty and human development 4200 journals join in theme issues on poverty and human development 5Global deal fuels QUT's world-changing research 2
Mouse Anti-20S proteasome subunits alpha 1 Monoclonal Antibody, Unconjugated, Clone MCP231 from Upstate
Rabbit Anti-Human TRIB1 / SKIP1 / Tribbles 1 Polyclonal Antibody, Unconjugated from IMGENEX
Mouse Anti-Pim-1 Monoclonal Antibody, Unconjugated, Clone 12H8 from Santa Cruz Biotechnology, Inc.
Rabbit Anti-Human Ets-1 Antibody, Unconjugated from Spring Bioscience
Biology Products: